SCHEMBL4354316

SCHEMBL4354316

CC(=O)c1cc(Cl)cc(NCc2ccccc2Sc2ccc(C)cc2)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.38
TP53 P04637 2/20 0.38
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
SLC6A4 P31645 2/20 0.37
LMNA P02545 3/20 0.37
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NOD2 Q9HC29 1/20 0.37
MAPT P10636 1/20 0.36
GFER P55789 1/20 0.36
POLB P06746 2/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP12 P39900 1/20 0.35
MMP14 P50281 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351160 0.94 SLC6A4 (0.43) BLMCYP2D6CYP2C9CYP2C19SMN1; SMN2
SCHEMBL4349809 0.93 SMN1; SMN2 (0.43) BLMCYP2D6CYP2C9CYP2C19SMN1; SMN2
SCHEMBL6247704 0.90 MAPT (0.41) BLMLMNAALDH1A1NPSR1MAPT
SCHEMBL4360001 0.89 POLB (0.50) TP53CYP2C9CYP2C19SMN1; SMN2LMNA
SCHEMBL4351799 0.89 LMNA (0.40) BLMSMN1; SMN2LMNAALDH1A1L3MBTL1
SCHEMBL4353891 0.89 SMN1; SMN2 (0.39) BLMCYP2D6CYP2C9CYP2C19SMN1; SMN2
SCHEMBL4354650 0.88 SLC6A2 (0.47) TP53SMN1; SMN2SLC6A4L3MBTL1POLB
SCHEMBL4348909 0.87 MAPT (0.45) CYP2D6CYP2C9CYP2C19SMN1; SMN2LMNA
SCHEMBL4343735 0.86 ITGB2 (0.39) SMN1; SMN2LMNAALDH1A1MAPTMEN1
SCHEMBL4353992 0.86 KMT2A (0.40) CYP2D6CYP2C9CYP2C19SMN1; SMN2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 BLM 4866/4885TP53 4868/4885CYP2D6 191/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 BLM 4860/4885TP53 4551/4885CYP2D6 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.